All You Need To Know About DRDO's New Anti-COVID-19 Drug 2-D
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
DRDO's new anti-Covid oral drug, 2-deoxy-D-glucose (2-DG), was recently granted emergency use approval by the Drug Controller General of India (DCGI) as an adjunct therapy in moderate cases of COVID-19. The 2-DG drug is expected to help hospitalised COVID-19 patients and reduce their supplemental oxygen dependence.

The anti-Covid oral drug has been developed by the Defence Research and Development Organisation's (DRDO's) leading laboratory- Institute of Nuclear Medicine and Allied Sciences (INMAS) in collaboration with Dr Reddy's Laboratories.

How was 2-DG developed? How were clinical trials conducted?

DRDO Project Director and Scientist of 2-DG, Dr Sudhir Chandana explained how the drug was developed. He stated that when the pandemic hit India in April 2020, they discovered that 2-DG halts the spread of COVID-19 inside the body cells. "After the findings, we asked the DCGI for permission to conduct clinical trials.

In May 2020, we got permission for the clinical trials. By the end of October 2020 we had completed the second phase of trials. Using standard care, 2 DG will be more beneficial for the Covid-19 patients," Chandana told. A total of 110 patients were part of the Phase-II clinical trials of DRDO's 2-DG drug. The results showed that in terms of improvement of vital signs of COVID-19 symptomatic patients there was a difference of 2.5 days compared to Standard of Care (SoC).

Approval for Phase - III clinical trials were granted in November 2020. These were conducted in 27 COVID-19 hospitals spread across several states. "Clinical trial results have shown that this molecule helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence," an official DRDO statement had explained earlier.

How 2-DG controls COVID-19 and reduces dependence on oxygen?

Explaining how 2-DG controls COVID-19 and reduces dependence on oxygen, Chandana told, "The 2 DG drug, like glucose, spreads through the body, reaches the virus-infected cells and prevents virus growth by stopping viral synthesis and destroys the protein's energy production. The drug also works on virus infection spread into lungs which help us to decrease patients dependability on oxygen".

How will 2-DG be manufactured?

The DRDO stated that the 2-deoxy-D-glucose (2-DG) drug can easily be produced in India and made available in plenty to the citizens as it is a generic molecule and analogue of glucose.

How is 2-DG be consumed?

The anti-COVID drug 2-DG has been developed in powder form and is ingested orally by dissolving it in water.

Dr. b●●●●n z●●●l and 29 others like this17 shares
Dr. R●●a K●●●●●a
Dr. R●●a K●●●●●a General Surgery
When will this drug be available for public in health care sectors and pharmacy ?
May 14, 2021Like1
Dr. R●●●●●●●●n S●●i
Dr. R●●●●●●●●n S●●i Radiology
Make it available very earlier to defeat disaster in sufficient =DrRKsoni
May 15, 2021Like1
Dr. D●●●●●●s T●●●●s
Dr. D●●●●●●s T●●●●s Pathology
Is there any bad effect on normal cell metabolism by competing with normal glucose metabolism, Is it approved by WHO?.
May 24, 2021Like